Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis

Background: It is unclear whether testing for novel risk factors, such as a cardiovascular genetic risk score (cGRS), improves clinical decision making or health outcomes when used for targeting statin initiation in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Our objective was to estimate the cost-effectiveness of cGRS testing to inform clinical decision making about statin initiation in individuals with low-to-intermediate (2.5%–7.5%) 10-year predicted risk of ASCVD. Methods and Results: We evaluated the cost-effectiveness of testing for a 27-single-nucleotide polymorphism cGRS comparing 4 test/treat strategies: treat all, treat none, test/treat if cGRS is high, and test/treat if cGRS is intermediate or high. We tested a set of clinical scenarios of men and women, aged 45 to 65 years, with 10-year ASCVD risks between 2.5% and 7.5%. Our primary outcome measure was cost per quality-adjusted life-year gained. Under base case assumptions for statin disutility and cost, the preferred strategy is to treat all patients with ASCVD risk >2.5% without cGRS testing. For certain clinical scenarios, such as a 57-year-old man with a 10-year ASCVD risk of 7.5%, cGRS testing can be cost-effective under a limited set of assumptions; for example, when statins cost $15 per month and statin disutility is 0.013 (ie, willing to trade 3 months of life in perfect health to avoid 20 years of statin therapy), the preferred strategy (using a willingness-to-pay threshold of $50 000 per quality-adjusted life-year gained) is to test and treat if cGRS is intermediate or high. Overall, the results were not sensitive to assumptions about statin efficacy and harms. Conclusions: Testing for a 27-single-nucleotide polymorphism cGRS is generally not a cost-effective approach for targeting statin therapy in the primary prevention of ASCVD for low- to intermediate-risk patients.

[1]  Olle Melander,et al.  Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials , 2015, The Lancet.

[2]  J. Pankow,et al.  Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. , 2007, American journal of epidemiology.

[3]  N. Sattar,et al.  Risk Prediction in Cardiovascular Medicine Integrating Information From Novel Risk Factors With Calculated Risks The Critical Impact of Risk Factor Prevalence , 2011 .

[4]  Milton C Weinstein,et al.  Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. , 2015, JAMA.

[5]  M. Pletcher,et al.  Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men , 2013, Journal of General Internal Medicine.

[6]  W. O'Fallon,et al.  Utilization of acute care services in the year before and after first stroke: A population-based study. , 1996, Neurology.

[7]  A. Fendrick,et al.  Cost-utility of aspirin and proton pump inhibitors for primary prevention. , 2011, Archives of internal medicine.

[8]  Joseph Loscalzo,et al.  Opportunities for the Cardiovascular Community in the Precision Medicine Initiative , 2016, Circulation.

[9]  D. Goff,et al.  Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment. , 2016, Journal of the American College of Cardiology.

[10]  John P. A. Ioannidis,et al.  Simple, standardized incorporation of genetic risk into non-genetic risk prediction tools for complex traits: coronary heart disease as an example , 2014, Front. Genet..

[11]  V. Salomaa,et al.  Genetic Risk Prediction and a 2-Stage Risk Screening Strategy for Coronary Heart Disease , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[12]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[13]  S. Kaul,et al.  Risk and the physics of clinical prediction. , 2014, The American journal of cardiology.

[14]  Nancy R. Cook,et al.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[15]  R. Green,et al.  Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). , 2016, Circulation.

[16]  R. Holloway,et al.  To test or not to test? , 1999, Neurology.

[17]  A Cecile J W Janssens,et al.  Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies—A targeted evidence-based review , 2010, Genetics in Medicine.

[18]  N. Paynter,et al.  Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use? , 2016, Circulation research.

[19]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[20]  Ellen Meara,et al.  Trends in medical spending by age, 1963-2000. , 2004, Health affairs.

[21]  Michael Pignone,et al.  Using the Coronary Artery Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis , 2014, Circulation. Cardiovascular quality and outcomes.

[22]  Andrew H Briggs,et al.  Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  Dermot F. Reilly,et al.  Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting , 2017, Circulation.

[24]  Peter Sandercock,et al.  Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[25]  Michael Pignone,et al.  Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A CostUtility Analysis , 2006, Annals of Internal Medicine.

[26]  Liming Cai,et al.  Health, life expectancy, and health care spending among the elderly. , 2003, The New England journal of medicine.

[27]  R. Goetzel,et al.  The Direct and Indirect Cost Burden of AcuteCoronary Syndrome , 2011, Journal of Occupational and Environmental Medicine.

[28]  C. O’Donnell,et al.  Genomic medicine for improved prediction and primordial prevention of cardiovascular disease. , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[29]  O. Franco,et al.  Incremental predictive value of 152 single nucleotide polymorphisms in the 10-year risk prediction of incident coronary heart disease: the Rotterdam Study. , 2015, International journal of epidemiology.

[30]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[31]  M. Pletcher,et al.  Interpreting Hemoglobin A1C in Combination With Conventional Risk Factors for Prediction of Cardiovascular Risk , 2015, Circulation. Cardiovascular quality and outcomes.

[32]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[33]  J. Menzin,et al.  One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. , 2008, Current medical research and opinion.

[34]  B. J. Gersh.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2011 .

[35]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[36]  M. Lemstra,et al.  Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. , 2012, The Canadian journal of cardiology.

[37]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[38]  Michael Pignone,et al.  Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. , 2007, Archives of internal medicine.

[39]  B. Friedman,et al.  Practical options for estimating cost of hospital inpatient stays. , 2002, Journal of health care finance.

[40]  M. Pletcher,et al.  Risk Prediction in Cardiovascular Medicine Evaluating the Clinical Utility of a Biomarker A Review of Methods for Estimating Health Impact , 2011 .

[41]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[42]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[43]  Stacey L. Sheridan,et al.  Quantifying the Utility of Taking Pills for Cardiovascular Prevention , 2015, Circulation. Cardiovascular quality and outcomes.

[44]  M. Blaha,et al.  Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. , 2014, Journal of the American College of Cardiology.

[45]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[46]  M. Budoff,et al.  Cost-Effectiveness of Coronary Artery Calcium Testing for Coronary Heart and Cardiovascular Disease Risk Prediction to Guide Statin Allocation: The Multi-Ethnic Study of Atherosclerosis (MESA) , 2015, PloS one.

[47]  G. Elwyn,et al.  Shared Decision Making—The Importance of Diagnosing Preferences , 2017, JAMA internal medicine.